- Cancer Type
- Biopsy Type
- Results Expected
What is FoundationFocus CDxBRCA?
FoundationFocus CDxBRCA is the first FDA-approved companion diagnostic assay for the treatment of ovarian cancer with Rubraca™ (rucaparib), a PARP inhibitor therapy for BRCA-mutated ovarian cancer.
Conventional tests look only for germline alterations in blood or saliva. FoundationFocus CDxBRCA analyzes ovarian cancer tumor tissue to detect both germline (inherited) and somatic (acquired) BRCA1/2 mutation types associated with response to PARP inhibitor therapy.1,2
1 in 4
women with ovarian cancer are BRCA+ (positive)
- First FDA-approved Next-Generation Sequencing (NGS) companion diagnostic for Rubraca
- Uncovers more BRCA mutations with a single tissue test
- Can help identify more women 2-5 who may benefit from PARP inhibitor therapy